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Equivalence of hydrofluoroalkane
(HFA) and chlorofluorocarbons (CFC)
formulations of inhaled
beclomethasone0954-6111/00/020177+07 $35?00/0These pharmacokinetic data would therefore suggest that
the HFA and CFC formulations of BDP are not
bioequivalent. Indeed, this has been shown with another
HFA-134a formulation of BDP metered dose inhaler (3M
Healthcare Limited, Loughborough, U.K.) where the
relative dose ratio for potency for HFA-BDP versus
CFC-BDP was 26, as assessed by comparing eects on
the steep part of the dose-response curve FEV1 in patients
with moderate to severe asthma (4).
Caution should therefore be exercised in interpreting the
data of Milanowski et al. in terms of making recommenda-
tions for directly substituting HFA (Norton Healthcare) for
CFC formulations of BDP metered dose inhaler on a
microgram equivalent basis. Properly designed clinical
trials using a dose-response comparison are required in
order to provide more rational dosing recommendations
when switching between the two products.
B. J. LIPWORTH AND C. M. JACKSON
Department of Clinical Pharmacology,
Ninewells Hospital and Medical School,
University of Dundee DD1 9SY, Scotland U.K.
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Dear Editor
Is inhaled beclomethasone (BDP)
with a non-CFC propellant equivalent
to the CFC propellant formulations?
The reformulation of beclomethasone dipropionate (BDP)
metered dose inhalers (MDIs), using hydrofluoroalkane
(HFA) propellants to replace chlorofluorocarbons (CFC) isWe read with interest the recent article of Milanowski et al.
(1) which reported an apparent equivalent anti-asthmatic
eect of low (400 mg per day) and high (2000 mg per day)
doses of HFA-134a (Norton Healthcare Ltd, London,
U.K.) and CFC formulations of beclomethasone dipropio-
nate (BDP). In order to evaluate the relative potency of two
inhaled corticosteroid formulations, it is necessary to
compare anti-asthmatic eects on the steep part of the
dose-response curve, preferably using at least three doses
(2). In the study of Milanowski et al. baseline values for
mean forced expiratory volume in 1 sec (FEV1) showed that
both groups were well matched for the low dose study (67%
predicted) and the high dose study (70% predicted). The
primary ecacy variable from the intent-to-treat popula-
tions showed no evidence of a dose-response eect between
2000 mg per day and 400 mg per day for either the CFC or
HFA formulations, in terms of the change in FEV1 between
baseline and end-point after 6 weeks of treatment. For
HFA-BDP the mean change in FEV1 was 04 l at 400 mg
and 02 l for 2000 mg, whilst for CFC-BDP values were 03 l
and 03 l, respectively. In other words, for the patients who
were studied, 400 mg day71 of either CFC or HFA-BDP
was on the plateau part of the dose-response curve. Hence it
is not possible to make any valid conclusions regarding
therapeutic equivalence from these data.
Had the authors evaluated doses of BDP less than 400 mg
per day on the steep part of the dose-response curve, it is
conceivable that dierences in anti-asthmatic potency
between the two formulations may have become evident.
In this respect we have recently performed a pharmacoki-
netic study to compare the systematic bioequivalence of a
1000 mg nominal dose of HFA-134a BDP metered dose
inhaler (as Beclazone-CFC free 250 mg per actuation,
Norton-Waterford, Ireland) or CFC containing metered
dose inhaler (Beclazone 250 mg per actuation) (3). The
HFA-134a BDP inhaler was identical to that used in the
study of Milanowski et al. Plasma levels of beclometha-
sone-17-monopropionate (17-BMP) were measured over a
12 h period after inhalation. The results showed mean
values for the area under the curve (AUC0–12) were 15 fold
greater, and mean values for maximum plasma concentra-
tion (Cmax) were 19 fold greater when comparing HFA-
BDP vs. CFC-BDP formulations. Furthermore, the 90%
confidence interval for the ratio of HFA-BDP to CFC-BDP
was outside of that established for bioequivalence for both
AUC (90% CI 133–195) and Cmax (90% CI 157–261).# 2000 HARCOURT PUBLISHERS LTD
